GlassScriptPhysician profile
Azfar B Sheikh
NPI 1407295736
$16,693.03
in general payments reported to CMS, 2019-2025
34 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,610 · 2020: $3,756 · 2021: $3,509 · 2022: $2,334 · 2023: $2,391 · 2024: $899 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,047 · Long Term Medical Supply Or Device Loan: $960 · Travel and Lodging: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,047.42 |
| Long Term Medical Supply Or Device Loan | $960.00 |
| Travel and Lodging | $477.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,242.92 | 2020-2025 | Optis, Amplatzer Amulet, Cardiomems |
| Boston Scientific Corporation | $3,937.12 | 2019-2025 | Watchman Flx, Resonate El Icd Vr, Bodyguardian |
| Angiodynamics, INC. | $3,004.54 | 2021-2025 | Venacure 1470 Pro, Auryon Laser System 100-120 Vac |
| Edwards Lifesciences Corporation | $1,334.26 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $629.19 | 2021-2025 | Repatha, Repatha |
| Medtronic, INC. | $571.97 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Linq II |
| Abiomed | $510.05 | 2020-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $301.11 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $281.59 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $280.15 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $197.62 | 2022-2024 | Verquvo |
| Cvrx, INC. | $185.85 | 2023-2025 | Barostim Neo System |
| Cardiovascular Systems INC. | $165.90 | 2020 | |
| Janssen Pharmaceuticals, INC | $142.77 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $120.63 | 2023-2025 | Camzyos, Eliquis |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $111.98 | 2024 | (Bh4) Igt Devices Undivided |
| Tactile Systems Technology INC | $81.67 | 2025 | Flexitouch Plus, Nimbl |
| Octapharma USA, INC. | $71.71 | 2025 | Fibryga |
| Actelion Pharmaceuticals US, INC. | $71.64 | 2024-2025 | Uptravi, Opsumit |
| Impulse Dynamics (USA) INC. | $57.93 | 2022-2023 | Optimizer |
| Pfizer INC. | $53.07 | 2021-2023 | |
| Inari Medical, INC. | $52.63 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Arbor Pharmaceuticals, INC. | $50.67 | 2022 | |
| Sanofi-Aventis U.S. LLC | $33.69 | 2022-2023 | |
| Endologix LLC | $29.26 | 2025 | Endocross Device, Torus Stent Graft System |
| Esperion Therapeutics, INC. | $26.44 | 2021-2022 | |
| Amarin Pharma, INC. | $22.32 | 2022 | |
| Eisai INC. | $21.84 | 2025 | |
| Inspire Medical Systems, INC. | $19.43 | 2025 | Inspire |
| Scpharmaceuticals INC. | $17.50 | 2025 | |
| Itamar Medical INC | $17.16 | 2023 | Watchpatone |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.95 | 2022 | |
| Atricure, INC. | $15.76 | 2022 | |
| Glaxosmithkline, LLC. | $15.71 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azfar Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.